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Abstract 
Introduction: The current study was designed to estimate the direct cost of noncompliance of diabetes patients to the US health 
system. Understanding these expenses can inform screening and education budget policy regarding expenditure levels that can be 
calculated to be cost-beneficial. 
Materials and Method: The study was conducted in three parts. First, a computer search of National Institutes of Health websites 
and professional society websites for organizations with members that treat diabetes, and a PubMed search were performed to 
obtain the numbers required for calculations. Second, formulas were developed to estimate the risk of non-compliance and 
undiagnosed diabetes. Third, risk calculations were performed using the information obtained in part one and the formulas 
developed in part two. 
Results: Direct risk reduction for diabetes-related kidney disease, stroke, heart disease, and amputation were estimated for 100% 
compliance with diabetes treatment.  Risk, case and yearly cost reduction calculated for a 100% compliance with diabetes treatment 
were 13.6%, 0.9 million and US$ 9.3 billion, respectively.  
Conclusion: Society, insurers, policy makers and other stakeholders could invest up to these amounts in screening, education and 
prevention efforts in an effort to reduce these costly and traumatic sequelae of noncompliant diabetes patients. 
 
 
Introduction 
Diabetes is the one of most common chronic diseases 
throughout the world.  In the USA, it was reported that 
annual care visits for diabetes total 28.6 million per year.
1 
Direct, indirect and total costs of diabetes to the USA`s health 
system per year were reported as $116 billion, $58 billion and 
$174 billion, respectively in 2007 dollars.
2 There are 23.6 
million people suffering from diabetes.
2 
 
It has been estimated that the cost of diabetes per patient 
was $7,372 in 2007 dollars ($ 174 billion / 23.6 million 
patients).  Treatments can control patients’ symptoms and 
can reduce comorbities and costs of diseases. But if patients 
cannot be diagnosed or be compliant with their treatments, 
the risks of comorbities and cost of comorbities may increase. 
There are huge numbers of undiagnosed and diagnosed but 
non-compliant patients.  It was reported that 17.9 million of 
23.6 million diabetes patients are aware they have it 
(approximately 76%)
 3 and nearly 72 (mean of 52-93%) 
percent of treated patients are compliant
4 with their 
treatment.  Based on the Markov Model presented in Figure 
1, only 55 percent of all diabetes patients are under full 
current treatment.  
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Diabetes doesn’t have known separate risk points for gender, 
age or blood glucose level. It has known risk points for only 
being diabetic or not being diabetic. Risk points, incidence 
and prevalence of diabetes were published by the National 
Diabetes Information Clearinghouse.
5,6 In addition, 
compliance and noncompliance of diabetics were reported in 
Breitscheidel’s review in 2009.
4 Prevalence of the 
comorbidities of diabetes was published by the Centers for 
Disease Control and Prevention’s Statistics
7,8,9 and the cost of 
comorbidities was published in Heart Disease and Stroke 
Statistics 2009
10, Atlas of Chronic Kidney Diseases 2009
11 and 
Kolansky’s
12 review which was published in 2009.  
 
Data were published about diabetes regarding incidence, 
prevalence, risks and comorbidities. However, there are some 
unknown areas such as the cost of non-compliance. The 
current study was designed to calculate the direct cost of 
non-compliant diabetes patients to the US health system. 
Understanding these expenses can inform screening and 
education budget policy regarding expenditure levels that can 
be calculated to be cost-beneficial. 
 
Materials and Method 
The study was conducted in three parts. First, a computer 
search of National Institutes of Health websites and 
professional society websites for organizations with members 
that treat diabetes, and a PubMed search were performed to Original Research  POLICY 
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obtain the numbers required for calculations. Second, 
formulas were developed to estimate the risk of 
noncompliance and undiagnosed diabetes. Third, risk 
calculations were performed using the information obtained 
in part one and the formulas developed in part two. 
 
First part 
An internet search was performed at the National Institutes 
of Health’s web sites. If there were data for the U.S. for 
diabetes which were published by the National Institutes of 
Health, they were included.  If data were not published by 
National Institutes of Health for the U.S, the web sites of the 
societies related to diabetes were searched. If data for the 
U.S. were not published in the society’s web sites, a PubMed 
search was performed. The published studies which include 
the widest and newest data in PubMed were included for 
calculations. After including data, estimations were made. 
The findings from the computer search and estimations are 
listed in Table 1. 
 
Second part 
Group percentages were estimated from the known 
numbers. Groups were defined as compliant, noncompliant 
and undiagnosed for diabetes. The undiagnosed group’s 
percentage was taken as 24% (1-0.76=0.24).
3  The compliant 
group’s percentage was taken as 55% depending on 
diagnosed group’s percentage (76%)
3 multiplied with 
compliant percentage (72% - mean of 52-93%)
4 (0.76 x 0.72 = 
0.55). The noncompliant group percentage was taken as 21% 
based upon 76%
3 (all diagnosed patients in all diabetes 
patients) and 55% (compliant patients in all diabetes patients) 
(0.76-0.55 = 0.21). 
 
Diabetes doesn’t have known separate risk points of 
comorbidities for each gender, age and blood glucose level. It 
has known risk points for only being diabetic or not being 
diabetic.  Risk points for comorbidities were estimated and 
risk points of sub-groups were calculated. The risk points 
were converted based on the compliance risk point as 1.  
 
The calculations were repeated for each group and these 
results were summed for calculating the main risk points of 
comorbidities which could be caused by diabetes.  The 
calculations were performed for compliant, noncompliant 
and undiagnosed groups. Then the calculation was performed 
for a 100% Compliant Strategy which means that all patients 
who were diagnosed with diabetes in the U.S. would take 
nearly 100% of doses prescribed or follow nearly 100% of 
recommendations. The Compliance Strategy led to control of 
blood HbA1c values, with blood HbA1c control defined as 
blood HbA1c values less than 6.5%
14. 
 
The difference in risk points of current patients and a 100% 
Compliant Strategy were used for calculation of cost 
reduction. The percentage of difference between risk points 
of current patients and a 100% Compliant Strategy were 
calculated. The percentage of risk reduction was used for 
calculation; the case reduction and the direct cost reduction 
by muliplication with current cases and direct costs. 
 
Formulas are shown below: 
1.  ∑( Percentage of Group
 * Risk Points) 
2.  Total Risk Point: ∑ Risk Points 
3.  % Risk Point Reduction for Compliance: 100 x (Total Base 
Risk Point -Total Estimated Compliance Risk Point)/Base 
Risk Point  
4.  Case Reduction: Base Disease Prevalence * % Risk Point 
Reduction 
5.  Cost of Illness per Patient: Cost of Illness / Prevalence of 
Illness 
6.  Cost of Illness Reduction: Case Reduction * Cost of Illness 
per Patient 
 
Example 1:  
Calculation of Kidney Diseases for Diabetes in Compliant Patients 
 
If risk point of compliance strategy is 1, the noncompliant risk point 
of kidney diseases according to increased risk point of kidney 
diseases in patients with diabetes in all kidney diseases
5 is 50%. 
= 1 / 50% = 2 
Compliant Group Base Risk Point = 0.55*1 (Percentage of Compliant 
Groups*Stroke Risk Point) = 0.55 
Incompliant Group Base Risk Point = 0.21*2 (Percentage of 
Incompliant Groups*Stroke Risk Point) = 0.42 
Undiagnosed Group Base Risk Point = 0.24*2 (Percentage of 
Undiagnosed Groups*Stroke Risk Point) = 0.48 
Total Base Risk Point = 0.55 + 0.42 + 0.48 = 1.45 
%100 Compliant Strategy Risk Point = (0.55+0.21)*1 + 0.48 = 1.24 
% Risk Point Reduction of Kidney Diseases for Compliance Strategy: 
(1.45-1.24)/1 * 100 = 14 % 
Case Reduction: 1,628,000 x 14 % = 235,779 
Cost of Illness per Patient: US$ 63 billion / 3,700,000 = US$ 17132 
Cost Of Illness Reduction: 235,779 * US $17132 = US $ 4.0 billion 
 
Risk Point: Risk point of comorbidities of diabetes at 
estimated situations. 
Base Risk Point: Risk point of comorbidities of diabetes at 
now. 
Total Risk Point: Risk point of comorbidities of diabetes at 
estimated situations. 
Total Base Risk Point: Risk point of comorbidities of diabetes 
now. 
 
Third Part 
The calculation was completed as shown in Example 1 for the 
diabetes compliance population stroke risk calculation. Original Research  POLICY 
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Estimations 
Percentage of compliance with diabetes treatment was 
estimated from the Breitscheidel et al. study.
4 It was reported 
that the range of compliance to diabetes treatment were 52-
93%. The mean value of 52% and 93% were taken for our 
calculations; which is 72%. 
 
The direct cost of lower extremity amputation was reported 
to be $24,000-40,000 in 1990 US$.
9 So these numbers were 
converted to 2009 US$ by adding a yearly 5% inflation rate 
and by calculating mean average which equaled US $ 80,000. 
In addition, heart failure risks were taken as heart diseases 
risks.  
 
Direct cost per patient was estimated from known direct 
costs and number of patients. For example, the direct cost of 
stroke per patient was calculated by dividing the direct cost 
of stroke by the numbers of adults who ever had a stroke. 
 
Risk points of undiagnosed and noncompliant patient were 
accepted as the same.  
 
Results 
Risk of kidney disease, stroke, heart disease (heart failure) 
and amputation caused directly by diabetes were calculated 
from known numbers and estimations. (Tables 1 & 2) Direct 
risk reduction caused by diabetes for kidney disease, stroke, 
heart disease, amputation were calculated for a 100% 
Compliant Situation (Table 3). 
 
Risk, case and cost reduction for kidney disease caused by 
diabetes with a 100% Compliant strategy were 14%, 0.23 
million and US$ 4.0 billion, respectively. Risk, case and cost 
reduction for stroke caused by diabetes with a 100% 
Compliant strategy were 17%, 0.18 million and US$ 1.2 
billion, respectively. Risk, case and cost reduction for heart 
diseases (heart failure) caused by diabetes with a 100% 
Compliant strategy were 10%, 0.48 million and US$ 3.3 
billion, respectively. Risk, case and cost reduction for 
amputation caused by diabetes with a 100% Compliant 
strategy were 12%, 0.008 million and US$ 0.6 billion, 
respectively. 
 
Total risk, case and yearly cost reduction calculated for a 
100% Compliant Strategy were 13.6%, 0.9 million and US$ 9.3 
billion, respectively.  
 
Discussion  
Noncompliance with prescribed drug regimens is a 
widespread phenomenon which results in needless trauma, 
decreased efficacy and is often associated with increased 
medical expenditures. Despite this, economic evaluations 
based on decision-analytic models rarely incorporate 
noncompliance to allow for the differences in compliance 
observed between controlled clinical trials and routine clinical 
practice.
15 
 
For example, a population based study was performed for 
comparing direct health care costs related to the treatment 
of osteoporosis and osteoporotic fractures among compliant 
and noncompliant users of alendronate and risedronate. 
Compared to compliant women, noncompliant women 
incurred significantly higher physician care and hospital care 
costs. Due to lower drug costs, total direct health care costs 
were lower among noncompliant women.
16 
 
In addition, a study was performed with kidney 
transplantation patients for examining relationships between 
compliance with allograft outcomes and costs. 
Immunosuppression medication possession ratios indicative 
of less than the highest quartile of compliance predicted 
increased risk of graft loss and elevated costs. These findings 
suggest that interventions to improve medication compliance 
among kidney transplant recipients should emphasize the 
benefits of maximal compliance, rather than discourage low 
compliance.
17 
 
Noncompliance with cardiovascular and antidiabetic 
medication is a significant problem. It was reported in 
Cramer’s review about compliance and persistence in the 
treatment of diabetes, hypertension and dyslipidaemia that 
30% of days 'on therapy' was not covered by medication and 
only 59% of patients were taking medication for more than 
80% of their days 'on therapy' in a year. Good compliance has 
a positive effect on clinical outcomes, suggesting that the 
management of CVD may be improved by improving patient 
compliance.
19 
 
Moreover, it was reported that direct risk reduction for 
stroke caused by hypertension, heart attack, kidney disease 
and heart disease was calculated for a 100% Compliant 
Strategy. Risk, case and cost reduction for a 100% Compliant 
Strategy for Hypertension were 32%, 8.5 million and US$ 72 
billion, respectively. 
20 
 
Limitations 
There were numerous assumptions and estimates such as 
multiplying the known numbers for calculating the 
percentages of compliant, noncompliant and undiagnosed 
groups in all diabetic populations. So it is necessary to 
perform this analysis depending on a separate trial which will 
report the percentage of compliant, noncompliant and 
undiagnosed groups. Original Research  POLICY 
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Risk and costs of eye diseases were taken as risk and costs of 
blindness which were lead by diabetes. It is necessary to 
perform this analysis depending on the actual risks and costs 
of blindness. 
 
Risk and costs of heart failure were taken as risk and costs of 
heart diseases which were led by diabetes. It is necessary to 
perform this analysis depending on the actual risks and costs 
of heart diseases. 
 
The number of patients who had kidney diseases, stroke, 
heart diseases and amputations which were led by diabetes 
was estimated from the published data. On the other hand, 
there were no precise incidence numbers for the 
comorbidities of diabetes. The published data were estimated 
from known numbers as well. It is necessary to perform this 
analysis depending on the clean incidence numbers for the 
comorbidities of diabetes. 
 
While this analysis will be first in the literature for diabetes, 
further analysis and estimations are needed to be performed 
for undiagnosed diabetes populations also. In total, it is 
possible to save nearly $8.1 billion per year by increasing the 
percentage of compliant patients in the ongoing treatment of 
diabetes.  These are hypothetical and full compliance would 
be hard or probably impossible to achieve but it reveals the 
amount of improvement that is possible. 
 
In conclusion, our analysis suggests that society, insurers, 
policy makers, and other stakeholders could invest up to 
these amounts in screening, education and prevention efforts 
in an effort to reduce these costly and traumatic sequelae of 
noncompliant diabetes patients. 
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Figure 1: Percentage of noncompliant, undiagnosed and untreated patients by Markov Model 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Diabetes 
Diagnosed 0.76 
Undiagnosed 0.24 
Compliant 0.72 
Noncompliant 0.28 
Full Treatment 0.55  
Not Full Treatment 0.45  Original Research  POLICY 
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Table 1: Numbers and estimation for calculation 
 
Data  Numbers 
USA Population
1  306 million 
Number of adults who ever had a stroke
7  6.5 million 
Number of adults with diagnosed kidney disease
7  3.7 million 
Number of adults with diagnosed heart disease
7  26.6 million 
Numbers of adults with diabetes
5  23.6 million 
Numbers of adult with amputations by diabetes(yearly)
5,6  71.000 
Percentage of diagnosed diabetes
5  76% 
Percentage of compliance to diabetes treatment
4  72%* (mean value of 
52-93%) 
Percentage of stroke by directly diabetes in all stroke
5  16% 
Percentage of kidney diseases by directly diabetes in all kidney diseases
5  44% 
Percentage of heart diseases by directly diabetes in all heart diseases
5  17%*  
Direct cost of stroke per patient
10  US$ 7,061* 
Direct cost of kidney diseases per patient
11  US$ 17,132* 
Direct cost of heart diseases per patient
10  US$ 6,879* 
Direct cost of amputation per patient
9  US$ 80,000* 
 *Estimated 
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Table 2: Risk Points & Estimated Risk Points for Diabetes 
 
Diabetes Groups  Kidney Diseases  Stroke  Heart Diseases 
(Heart Failure) 
Amputation 
   
  Risk 
Rdct. 
Est. 
Risk 
Risk 
Rdct. 
Est. 
Risk 
Risk 
Rdct. 
Est. 
Risk 
Risk 
Rdct. 
Est. 
Risk 
Compliance   
50%
5 
1   
57%
5 
1   
42%
5 
1   
56%
5 
1 
Noncompliant  2  1.78  1.66  2.32 
Undiagnosed  2  1.78  1.66  2.32 
 
 
 
 
 
Table 3: Estimation of Effect of 100% Compliant Strategy for Diabetes 
Data  100% Compliant Strategy for Diabetes 
Direct Risk Reduction  Direct Case 
Reduction 
Direct Cost Reduction 
(US$) 
Kidney Disease 
Estimation 
14%  0.23 million  4.0 billion 
Stroke Estimation  17%  0.18 million  1.2 billion 
Heart Disease(Heart 
Failure) Estimation 
10%  0.48 million  3.3 billion 
Amputation 
Estimation 
12%  0.008 million  0.6 billion 
Total  13.67 % (mean value)  0.90 million  9.3 billion 
 
 